Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/1061186X.2020.1797754 http://scihub22266oqcxt.onion/10.1080/1061186X.2020.1797754 32700580!ä!32700580 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32700580&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Drug+Target 2020 ; 28 (7-8): 683-699 Nephropedia Template TP {{tp|p=32700580|t=2020. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety |pdf=|usr=}}{{32700580}} gab.com Text Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety JO: J Drug Target http://www.kidney.de/pget.php?&tw=1&pmid=32700580 #FOAvip The COVID-19 pandemic is caused by the severe acute-respiratory-syndrome-coronavirus-2 that uses ACE2 as its receptor. Drugs that raise serum/tissue ACE2 levels include ACE inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) that are commonly used in patients with hypertension, cardiovascular disease and/or diabetes. These comorbidities have adverse outcomes in COVID-19 patients that might result from pharmacotherapy. Increasing ACE2 could potentially increase the risk of infection, severity or mortality in COVID-19 or it might be protective as it forms angiotensin-(1-7) which exhibits anti-inflammatory/anti-oxidative effects and prevents diabetes- and/or hypertension-induced end-organ damage. Thus, there existed clinical uncertainty. Here, we review studies implicating 15 classes of drugs in increasing ACE2 levels in vivo and the available literature on the clinical safety of these drugs in COVID-19 patients. Further, in a re-analysis of clinical data from a meta-analysis of 9 studies, we show that ACEIs/ARBs usage was not associated with an increased risk of all-cause mortality. Literature suggests that ACEIs/ARBs usage generally appears to be clinically safe though their use in severe COVID-19 patients might increase the risk of acute renal injury. For definitive clarity, further clinical and mechanistic studies are needed in assessing the safety of all classes of ACE2 raising medications. Twit Text FOAVip Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety ????J Drug Target http://www.kidney.de/pget.php?&tw=1&pmid=32700580 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32700580 #FOAvip English Wikipedia <ref>{{Cite pmid|32700580}}</ref> Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety #MMPMID32700580 Akhtar S; Benter IF; Danjuma MI; Doi SAR; Hasan SS; Habib AM J Drug Target 2020[Aug]; 28 (7-8): 683-699 PMID32700580show ga The COVID-19 pandemic is caused by the severe acute-respiratory-syndrome-coronavirus-2 that uses ACE2 as its receptor. Drugs that raise serum/tissue ACE2 levels include ACE inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) that are commonly used in patients with hypertension, cardiovascular disease and/or diabetes. These comorbidities have adverse outcomes in COVID-19 patients that might result from pharmacotherapy. Increasing ACE2 could potentially increase the risk of infection, severity or mortality in COVID-19 or it might be protective as it forms angiotensin-(1-7) which exhibits anti-inflammatory/anti-oxidative effects and prevents diabetes- and/or hypertension-induced end-organ damage. Thus, there existed clinical uncertainty. Here, we review studies implicating 15 classes of drugs in increasing ACE2 levels in vivo and the available literature on the clinical safety of these drugs in COVID-19 patients. Further, in a re-analysis of clinical data from a meta-analysis of 9 studies, we show that ACEIs/ARBs usage was not associated with an increased risk of all-cause mortality. Literature suggests that ACEIs/ARBs usage generally appears to be clinically safe though their use in severe COVID-19 patients might increase the risk of acute renal injury. For definitive clarity, further clinical and mechanistic studies are needed in assessing the safety of all classes of ACE2 raising medications. |Angiotensin Receptor Antagonists/adverse effects/pharmacology[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/adverse effects/pharmacology[MESH] |Animals[MESH] |Betacoronavirus/isolation & purification[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Cardiovascular Diseases/complications/drug therapy[MESH] |Coronavirus Infections/*drug therapy/mortality/physiopathology[MESH] |Diabetes Mellitus/drug therapy/physiopathology[MESH] |Humans[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/drug effects/*metabolism[MESH] |Pneumonia, Viral/*drug therapy/mortality/physiopathology[MESH] |Risk Factors[MESH]Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs a(epmc).pdf DeepDyve Pubget Overpricing